[1]任小苗,赵 静.肿瘤减灭术后静脉腹腔联合化疗治疗晚期上皮性卵巢癌效果及对患者血清B7-H4蛋白、E-选择素水平的影响[J].陕西医学杂志,2021,50(10):1235-1238.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.014]
　REN Xiaomiao,ZHAO Jing.Effect of intravenous intraperitoneal combined chemotherapy for advanced epithelial ovarian cancer after tumor reduction surgery and its effect on serum B7-H4 protein and E-selectin levels[J].,2021,50(10):1235-1238.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.014]
点击复制

肿瘤减灭术后静脉腹腔联合化疗治疗晚期上皮性卵巢癌效果及对患者血清B7-H4蛋白、E-选择素水平的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年10期
页码:
1235-1238
栏目:
临床研究
出版日期:
2021-10-05

文章信息/Info

Title:
Effect of intravenous intraperitoneal combined chemotherapy for advanced epithelial ovarian cancer after tumor reduction surgery and its effect on serum B7-H4 protein and E-selectin levels
作者:
任小苗; 赵 静
(西安市人民医院 西安市第四医院,陕西 西安 710004)
Author(s):
REN Xiaomiao; ZHAO Jing
(Xi'an People's Hospital,Xi'an 710004,China)
关键词:
晚期上皮性卵巢癌;  肿瘤减灭术;  静脉腹腔联合化疗;  预后;  B7-H4蛋白;  E-选择素;  相关性
Keywords:
Advanced epithelial ovarian cancer;  Tumor reduction surgery;  Intravenous intraperitoneal combined chemotherapy;  Prognosis;  B7-H4 protein;  E-selectin;  Correlation
分类号:
R 737.31
DOI:
DOI:10.3969/j.issn.1000-7377.2021.10.014
文献标志码:
A
摘要:
目的:研究了肿瘤减灭术后静脉腹腔联合化疗治疗晚期上皮性卵巢癌(EOC)的效果及对血清B7-H4蛋白、E-选择素水平的影响。方法:纳入晚期EOC患者150例,均行肿瘤减灭术和静脉腹腔联合化疗。记录治疗有效率、治疗前后B7-H4蛋白、E-选择素水平。使用二元Logistic回归分析影响晚期EOC患者治疗反应的危险因素。使用ROC曲线分析B7-H4蛋白、E-选择素对晚期EOC患者治疗反应的预测价值。结果:肿瘤减灭术后静脉腹腔联合化疗对晚期EOC患者的治疗有效率为77.33%。治疗后患者B7-H4蛋白和E-选择素水平均明显低于治疗前(均P<0.05)。治疗前B7-H4蛋白水平、治疗前E-选择素水平、肿瘤减灭术后残余病灶直径≥1 cm均为晚期EOC患者治疗反应的独立影响因素(均P<0.05)。ROC曲线显示,B7-H4蛋白和E-选择素对晚期EOC患者治疗反应的预测中,AUC分别为0.727(95%CI:0.617～0.837)和0.799(95%CI:0.707～0.892)。结论:肿瘤减灭术后静脉腹腔联合化疗对晚期EOC患者的治疗有效率为77.33%,治疗前B7-H4蛋白、E-选择素水平均为晚期EOC患者治疗反应的独立影响因素,并可作为晚期EOC患者治疗反应预测的有效指标。
Abstract:
Objective:To study the effect of intravenous intraperitoneal combined chemotherapy for advanced epithelial ovarian cancer(EOC)after tumor reduction surgery and its effect on serum B7-H4 protein and E-selectin levels.Methods:150 patients with advanced EOC were included,all underwent tumor reduction surgery and intravenous intraperitoneal combined chemotherapy.The effective rate of treatment,B7-H4 protein and E-selectin levels before and after treatment were recorded.Binary Logistic regression was used to analyze the risk factors that affected the treatment response of patients with advanced EOC.The ROC curve was used to analyze the predictive value of B7-H4 protein and E-selectin on the treatment response of patients with advanced EOC.Results:The effective rate of intravenous intraperitoneal combined chemotherapy for patients with advanced EOC after tumor reduction surgery was 77.33%.After treatment,the patients' B7-H4 protein and E-selectin levels were significantly lower than those before treatment(all P<0.05).The level of B7-H4 protein before treatment,the level of E-selectin before treatment,and the residual lesion diameter ≥1 cm after tumor reduction were all independent factors influencing the treatment response of patients with advanced EOC(all P<0.05).The ROC curve showed that the AUC of B7-H4 protein and E-selectin for the treatment response of patients with advanced EOC were 0.727(95%CI:0.617-0.837)and 0.799(95%CI:0.707-0.892),respectively.Conclusion:The effective rate of intravenous intraperitoneal combined chemotherapy for patients with advanced EOC after tumor reduction surgery was 77.33%.The levels of B7-H4 protein and E-selectin before treatment are independent factors influencing the treatment response of patients with advanced EOC,and can be used as effective indicators for the prediction of treatment response of patients with advanced EOC.

参考文献/References:

[1] 钟 亮,刘清壮,蔡茂德.Ⅲ、Ⅳ期上皮性卵巢癌术后腹腔辅助化疗临床观察[J].陕西医学杂志,2020,49(2):193-196.
[2] 刘瑞丽,刘小红,李会荣,等.主动循环腹腔热灌注化疗治疗卵巢癌伴腹腔积液效果观察[J].陕西医学杂志,2019,48(12):1630-1633.
[3] 章晓洁,李怀芳,初 磊,等.B7-H4和B7-H6在卵巢癌中的表达及意义[J].中国临床医学,2018,25(6):963-966.
[4] 梅 晗,周 辉,陈煜枫,等.外周血E-selectin、P-selection及K-ras基因突变水平在胰腺癌中的表达及意义[J].解放军医药杂志,2021,33(1):16-19,26.
[5] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004(2):25-30,51.
[6] 徐 林.紫杉醇联合顺铂腹腔注射晚期卵巢癌患者的疗效及对生存期的影响[J].实用癌症杂志,2018,33(4):638-640.
[7] 林月丽,吴明燕,陈 慧.紫杉醇联合顺铂不同给药途径对晚期卵巢癌疗效的影响研究[J].解放军预防医学杂志,2019,37(6):140-141.
[8] 赵红果,刘爱珍,宋芷霜,等.紫杉醇联合顺铂腹腔和静脉双途径治疗晚期卵巢癌的疗效分析[J].现代诊断与治疗,2018,29(5):710-712.
[9] 张丽静,薛惠英,胡 捷.B7H3、B7H4在上皮性卵巢癌组织及血清中的表达及其临床意义[J].实用癌症杂志,2021,36(1):49-52.
[10] 周 敏,覃小敏,李 琳,等.主动循环热灌注化疗对卵巢癌腹水疗效及HE4、CA125、VEGF和B7-H4水平的影响[J].中国妇产科临床杂志,2021,22(1):17-19.
[11] 于文亮.卵巢癌患者血清中ROBO4、sB7-H4含量与肿瘤病理特征的相关性研究[J].海南医学院学报,2019,25(11):877-880.
[12] 王禹涵,李佩玲.卵巢癌肿瘤标志物的研究进展[J].现代肿瘤医学,2018,26(12):1966-1969.
[13] 靳 枫,余少康,李 柱,等.胃癌患者血清miR-183 E-selectin AMBP的变化及与临床病理的关系[J].河北医学,2019,14(12):109-112.
[14] 张家艳,李燕舞,范华颖,等.术前血清E-selectin与ICAM-1及MMP-2表达与肺癌手术患者预后的关系[J].河北医学,2020,26(11):15-20.
[15] 常云松,付 颖,张 震,等.靶向E-选择素的新型荧光探针的设计合成与生物学评价[J].国际药学研究杂志,2020,47(2):34-41,55.
[16] 庄文亭,于世娇,赵淑华.肿瘤标志物对卵巢癌诊断的研究进展[J].中国实验诊断学,2019,23(2):358-361.
[17] 张 震,赵 龙,付 颖,等.E-选择素肽配体及其与羟基喜树碱的偶联物合成与抗肿瘤活性评价[J].天津科技大学学报,2019,34(6):20-24.
[18] 尹义学,蔡彬彬,司 亮,等.自然腔道取出标本手术对直肠癌患者术后康复及免疫功能的影响分析[J].中国普通外科杂志,2019,28(4):392-398.
[19] 王秋宇,李晓翔,朱军义.上皮性卵巢癌初次肿瘤细胞减灭术后复发情况及影响因素分析[J].现代肿瘤医学,2019,27(2):132-135.
[20] 柳 禹,曹莉莉,周 莉,等.晚期上皮性卵巢癌经腹腔镜和开腹的初次肿瘤细胞减灭术或中间型减瘤术的临床对比研究[J].实用妇产科杂志,2020,36(4):298-302.

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(2018SF-147)
更新日期/Last Update: 2021-10-08